India, June 11 -- Genmab A/S (GMAB) on Thursday presented new subgroup data from the Phase 3 EPCORE FL-1 trial showing that epcoritamab in combination with rituximab and lenalidomide (R2) delivered consistent efficacy and a manageable safety profile across multiple patient subgroups with relapsed or refractory follicular lymphoma.
The post-hoc analysis evaluated outcomes across clinically relevant subgroups, including patients with different Follicular Lymphoma International Prognostic Index (FLIPI) scores, progression of disease within 24 months of frontline treatment (POD24), and varying levels of patient fitness.
The analysis showed progression-free survival benefits consistently favored the epcoritamab combination, with hazard ratios ...